1887

n South African Gastroenterology Review - Effect of tegaserod on quality of life and symptom relief in women with irritable bowel syndrome with constipation in South Africa : research

USD

 

Abstract

&lt;I&gt;Background:&lt;/I&gt; Tegaserod is a promotility agent with proven efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). &lt;br&gt;&lt;I&gt;AIM:&lt;/I&gt; Assess tegaserod's effect on quality of life (QOL) and symptom relief in South African patients. &lt;br&gt;&lt;I&gt;Methods:&lt;/I&gt; Women >18 years old meeting Rome II criteria for IBS-C were enrolled in a prospective, open-label, multi-center study in South Africa, consisting of a 2-week treatment-free baseline period, followed by a 4-week tegaserod 6 mg b.i.d. treatment period. QOL was assessed using the IBS-QOL questionnaire, at -2 weeks, baseline and 4 weeks; symptom relief was evaluated with daily diaries and weekly assessments of overall symptom relief. &lt;br&gt;&lt;I&gt;Results:&lt;/I&gt; Of the 242 women enrolled, 210 completed the study visits and questionnaires. Compared with baseline, tegaserod significantly improved overall QOL and domains at Week 4 (p values<0.001). Overall symptom relief was reported by 68.7% of patients. At Week 4 tegaserod significantly improved number of bowel movements, stool form, straining, sense of incomplete evacuation, abdominal pain and bloating (p values<0.001). Significant improvements were observed at Week 1 and sustained throughout the study. <br><I>Conclusions:</I> Tegaserod significantly improves QOL and relieves the multiple symptoms associated with IBS-C. Symptom improvement was observed early and was sustained through study end.

Loading

Article metrics loading...

/content/medgas/4/1/EJC71916
2006-03-01
2016-12-02
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error